Table 3.
Montha | Platelet count categoryb | Group |
P valuec | |
---|---|---|---|---|
Prophylaxis n (%) | Nonprophylaxis n (%) | |||
1 | 1 | 10 (5.9) | 5 (5.4) | 1.000 |
2 | 64 (37.9) | 16 (17.2) | ||
3 | 95 (56.2) | 71 (77.2) | ||
2 | 1 | 14 (8.3) | 4 (4.4) | 0.309 |
2 | 57 (33.7) | 14 (15.2) | ||
3 | 98 (58.0) | 74 (80.4) | ||
3 | 1 | 14 (8.3) | 3 (3.3) | 0.187 |
2 | 58 (34.3) | 14 (15.2) | ||
3 | 97 (57.4) | 74 (81.5) | ||
4 | 1 | 13 (7.7) | 3 (3.3) | 0.185 |
2 | 57 (34.3) | 13 (15.2) | ||
3 | 97 (58.0) | 72 (81.5) | ||
5 | 1 | 13 (8.3) | 4 (4.3) | 0.309 |
2 | 44 (26.6) | 16 (18.5) | ||
3 | 107 (65.1) | 66 (77.2) | ||
6d | 1 | 10 (5.9) | 4 (4.4) | 0.776 |
2 | 43 (26.6) | 12 (14.1) | ||
3 | 110 (67.5) | 69 (81.5) |
There was no statistically significant difference in platelet counts at baseline between the 2 groups.
Month after start of treatment.
Platelet count categories (per μl): 1: ≤80,000; 2: 81,000−150 000; 3: ≥150,000.
Fisher exact test.
One month after stopping treatment.